"The conference was a success for providing a platform where the best minds in the stem cell research industry can share their work. During the conference, we received favorable response to our neural crest stem cell technology, allowing us to accumulate a list of potential clients for the technology. We can say with confidence that the future of our company is positive and our commercialization strategy is strong," says Dr. Cyndi Chen.

About Cambridge Healthtech Institute

Cambridge Healthtech Institute's (CHI) renowned conferences are the underpinning for all our other information resources. Each year, approximately 60 conferences are held throughout the U.S. and Europe. Conference programs are designed to be a useful, timely and effective supplement to specialized journals, newsletters and other meetings. We strive to develop quality programs that provide valuable new insights and competing points of view, while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on new products and technology still in the evaluation stage. Experts from both academic and commercial laboratories present their most current scientific research in a forum that features panel discussions and audience participation.

Additionally, our conferences provide organizations with a unique opportunity to reach a highly targeted scientific audience. CHI events facilitate interaction with key decision-makers from leading pharmaceutical and biotech organizations. This format offers companies who sponsor or exhibit at a CHI event direct access to individuals who are interested in their products and services. In the past 13 years, CHI has produced over 300 conferences, attracting more than 40,000 attendees from around the world.

Safe Harbor Statement Forward-Looking Statements

Included in this release are certain "forward-looking" statements involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the U.S. BioDefense's financial performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to the U.S. BioDefense's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Information with respect to important factors that should be considered is contained in the U.S. BioDefense's Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. U.S. BioDefense does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.